MedTrace Logo

ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP

NCT01971684 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2020-05-21

No results posted yet for this study

Summary

The purpose of this study is to understand physician treatment decisions in selecting specific second line treatments in pediatric ITP and to determine the effectiveness of different second line ITP treatments. Eligible patients are those ages 1-18 years who are starting on a new second line treatment for ITP, defined as any treatment other than IVIG, steroids, anti-D globulin, or aminocaproic acid. Enrolled patients remain on the study for approximately one year.

Conditions

Interventions

DRUG

Second Line ITP agents

The treating physicians will select the second line agent and clinical data will be collected.

Sponsors & Collaborators

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2017-04-30
Completion
2017-04-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01971684 on ClinicalTrials.gov